X-100407263-G-T
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM1PM2PP3_StrongPP5_Moderate
The NM_001184880.2(PCDH19):c.1335C>A(p.Asp445Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★).
Frequency
Consequence
NM_001184880.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 10 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCDH19 | NM_001184880.2 | c.1335C>A | p.Asp445Glu | missense_variant | Exon 1 of 6 | ENST00000373034.8 | NP_001171809.1 | |
PCDH19 | NM_001105243.2 | c.1335C>A | p.Asp445Glu | missense_variant | Exon 1 of 5 | NP_001098713.1 | ||
PCDH19 | NM_020766.3 | c.1335C>A | p.Asp445Glu | missense_variant | Exon 1 of 5 | NP_065817.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCDH19 | ENST00000373034.8 | c.1335C>A | p.Asp445Glu | missense_variant | Exon 1 of 6 | 1 | NM_001184880.2 | ENSP00000362125.4 | ||
PCDH19 | ENST00000255531.8 | c.1335C>A | p.Asp445Glu | missense_variant | Exon 1 of 5 | 1 | ENSP00000255531.7 | |||
PCDH19 | ENST00000420881.6 | c.1335C>A | p.Asp445Glu | missense_variant | Exon 1 of 5 | 1 | ENSP00000400327.2 |
Frequencies
GnomAD3 genomes Cov.: 24
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 24
ClinVar
Submissions by phenotype
Glycine encephalopathy;C1848137:Developmental and epileptic encephalopathy, 9 Pathogenic:1
- -
not provided Pathogenic:1
This variant is denoted p.Asp445Glu (GAC>GAA): c.1335 C>A in exon 1 of the PCDH19 gene (NM_001105243.1). The Asp445Glu missense change has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 6,300 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project or among the various ethnic groups studied in the 1000 Genomes Project, indicating it is not a common benign variant in these populations. The amino acid substitution is conservative as both Aspartic acid and Glutamic acid are negatively charged, polar amino acid residues. However, Asp445Glu alters a highly conserved position in the fourth extracellular cadherin repeat domain of the protein and other missense mutations in this domain have been published in association with epilepsy (Dibbens et al., 2008; Specchio et al., 2011). In addition, multiple in-silico algorithms predict Asp445Glu may be damaging to the structure/function of the protein. Therefore, based on the currently available information, Asp445Glu is a strong candidate for a disease-causing mutation, although the possibility that it is a benign variant cannot be excluded. The variant is found in EPILEPSY panel(s). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at